Results 161 to 170 of about 524,934 (294)

Comparing Heparin and Heparin Mimetics in Targeting Immunomodulatory Proteins from Platelets to Activate T Cell-Dependent Immune Response in Oncology. [PDF]

ACS Pharmacol Transl Sci
Nekipelov K, Otto S, Henseler M, Vidal-Y-Sy S, Al Nahain A, Gorzelanny C, Ferro V, Bendas G.   +7 more
europepmc   +1 more source

Intravenous lanadelumab for the treatment of moderately ill COVID‐19 patients

British Journal of Clinical Pharmacology, EarlyView.
Aims Kallikrein‐kinin system (KKS) dysregulation is hypothesized to play a pathogenetic role in COVID‐19‐associated pulmonary oedema. To investigate the efficacy and safety of intravenous lanadelumab, a monoclonal antibody that inhibits plasma kallikrein, in COVID‐19, we conducted a phase 2, open‐label, randomized‐controlled, proof‐of‐concept ...
Job J. Engel, Christine van Linge, W. Joost Wiersinga, Ilse J. E. Kouijzer, Quirijn de Mast, Robert‐Jan Hassing, Danique J. H. Huijbens, Helen L. Leavis, Roger Schutgens, Coen Maas, Kit C. B. Roes, Frank L. van de Veerdonk, Roger Brüggemann   +12 more
wiley   +1 more source

Dichotomous SMAD2/3 regulation and selective antihypertrophic activity of heparin during in vitro chondrogenesis of mesenchymal stromal cells. [PDF]

Cell Mol Biol Lett
Schmidt S, Chasan S, Dietmar HF, Klampfleuthner FAM, Hesse E, Walker T, Freudenberg U, Richter W, Diederichs S.   +8 more
europepmc   +1 more source

Neuronal differentiation and tissue engineering strategies for central neurous system injury repair

BMEMat, EarlyView.
This review outlines tissue engineering advances for central nervous system (CNS) injury treatment, focusing on three core components: seed cells, inductive factors, and scaffold materials, with evaluation of their respective strengths and limitations. Tissue engineering for CNS injury repair.
Zhuqing Xia, Jinghui Zhang, Na Ren, Shuping Wang, Congcong Zhang, Nik Ahmad Nizam Nik Malek, Wan Hairul Anuar Kamaruddin, Chao Liu, Chunhui Sun, Jingang Wang   +9 more
wiley   +1 more source

Heparin protocols in cardiovascular surgery for antiphospholipid syndrome: a clinical case report. [PDF]

Egypt Heart J
Nakajima T, Iba Y, Shibata T, Miura S, Hasegawa T, Kouzu H, Kawaharada N.   +6 more
europepmc   +1 more source

Radial capacity and hemodynamics evaluation in vitro and implantable feasibility validation in vivo of thinner bioresorbable polymer vascular stents

BMEMat, EarlyView.
A series of in vitro experiments, numerical simulations and in vivo experiments were conducted to jointly evaluate the effects of different thicknesses of bioabsorbable polymer vascular stents on their radial capacity, hemodynamics and in vivo outcomes.
Chong Chen, Tao Li, Zhongyou Li, Jingyuan Zhou, Zhuo Zhang, Yan Xiong, Rifang Luo, Yu Chen, Yunbing Wang, Ping Fu   +9 more
wiley   +1 more source

Heparan sulfate as an attachment factor for ASFV is restricted by host HB-EGF. [PDF]

Cell Mol Life Sci
Xue W, Yang F, Zhang Z, Zhang X, Yang Y, Li Y, Feng Z, Li Y, Lan X, Zheng H, Zhu Z, Zhang S.   +11 more
europepmc   +1 more source

Overcoming intranasal delivery barriers with ultrastable polyzwitterionic siRNA nanocages for enhanced glioblastoma therapy

BMEMat, EarlyView.
A ROS‐responsive, zwitterionic nanocage enables stable, intranasal siRNA delivery to glioblastoma, promoting deep tumor penetration via non‐degradative pathways and trigeminal nerve transport. This platform achieves durable gene silencing and tumor suppression, offering a non‐invasive, storage‐stable strategy for treating glioma and other neurological ...
Jingwen Xie, Jingxing Si, Xiaobei Deng, Jing Tan, Ruijie Zhu, Jizhou Qi, Gaoxia Ma, Bin Wang, Yi Wang, Yunzhou Guo, Yuping Chen, Shiqun Shao, Youqing Shen   +12 more
wiley   +1 more source

Early prophylactic heparin use is associated with reduced mortality in patients with non-traumatic subarachnoid hemorrhage. [PDF]

Front Neurol
Xiang H, Chen X, Wang L, Lai W.
europepmc   +1 more source

Heparin Action [PDF]

Circulation, 1974
openaire   +2 more sources